Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous Polyposis
Part of the
Advances in Experimental Medicine and Biology
book series (AEMB, volume 470)
Sulindac sulfone (Exisulind), a metabolite of the non-steroidal anti-inflammatory drug, sulindac, was evaluated for its effects on the development of rectal polyps in patients with familial adenomatous polyposis. Three cohorts of 6 patients each were given doses of 200, 300, or 400 mg Exisulind twice daily. Hepatotoxicity, shown by elevation in blood transaminase levels, was the dose-limiting toxicity and occurred at the 400 mg bid dose. Due to this toxicity, all patients treated with the 400 mg dose were subsequently reduced to the 200 mg dose level. Subsequently, 2 of the 6 patients were dose-escalated to 400 mg bid dose. The patients were treated with Exisulind for a period of six months. Sixteen of 18 patients had regression of small polyps (≥6mm in diameter) characterized by a flattening of the polyps and a macular “halo” appearance. Histopathologic examination of the polyp biopsy specimens showed a marked increase in the proportion of mucin producing cells in the glands after treatment with Exisulind at all dose levels. Ki-67 staining, a measure of cell proliferation, was higher in the polyps than in normal mucosa. There was no significant change in the proliferation index between baseline and six month values in any of the groups treated with Exisulind or in normal tissues. The median apoptotic labeling index, as determined by the TUNEL technique, was higher in the polyps than in normal-appearing mucosa. Overall, there was no significant change in the apoptotic labeling index between baseline and 6 months in normal-appearing mucosa however, the index in polyps was increased. These results suggest that treatment of FAP patients with Exisulind for a period of six months may lead to regression of small polyps, and that the mechanisms of Exisulind—induced regression appear to be through stimulation of mucus differentiation and apoptosis in glandular epithelium.
KeywordsFamilial Adenomatous Polyposis Subtotal Colectomy Familial Adenomatous Polyposis Patient Rectal Polyp Small Polyp
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bussey H.J.R., Eyers A.A., Ritchie S.M., and Thompson J.P.S. The rectum in adenomatous polyposis: the St. Mark’s policy. Br. J. Surg.
72:S29–S35, 1985.PubMedCrossRefGoogle Scholar
Burt R.W. and Gorden J. The genetic and molecular diagnosis of adenomatous polyposis coli. Gastroenterology
104:1211, 1993.PubMedGoogle Scholar
Rigas B., Goldman I.S., and Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med.
122:518, 1993.PubMedGoogle Scholar
Waddell W.R., Ganser G.F., Cerise E.J., and Loughry R.W. Sulindac for polyposis of the colon. Am. J. Surg.
157:175, 1989.PubMedCrossRefGoogle Scholar
Rigau J., Pique J.M., Rubio E., Planas R., Tarrech J.M., and Bordas J.M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med.
115:952, 1991.PubMedGoogle Scholar
Labayle D., Fischer D., Vielh P., et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology
101:635, 1991.PubMedGoogle Scholar
Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., and Celano P. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl. J. Med.
328:1313, 1993.PubMedCrossRefGoogle Scholar
Moorghen M., Ince P., Finney K.J., Sunter J.P., Appleton D., and Watson A.J. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol.
156:341, 1988.PubMedCrossRefGoogle Scholar
Skinner S.A., Penney A.G., and O’Brian P.E. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg.
126:1094, 1991.PubMedCrossRefGoogle Scholar
Shen T.Y., Ham E.A., Cirillo V.J., et al. Prostaglandin synthetase inhibitors. In: Robinson III and Vane J.R. (eds) Prostaglandin synthetase inhibitors, Their effects on physiological functions and pathological states. Raven Press, New York, 18, 1974.Google Scholar
Shen T.Y. and Winter C.A. Chemical and biological studies of indomethacin, sulindac, and their analogs. Adv. Drug. Res.
12:90, 1977.PubMedGoogle Scholar
Piazza G.A., Kulchak Rahm A.L., Krutzsch M., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res.
55:3110, 1995.PubMedGoogle Scholar
Piazza G.A., Alberts D.S., Hixson L.J., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res.
57(14):2909, 1997.PubMedGoogle Scholar
van Stolk R., Hayton W.L., Chan K.K., et al. Safety and tolerability of sulindac sulfone (Exisulind) in patients with familial adenomatous polyposis, results of a phase I and pharmacokinetic trial. Gastroenterology
, submitted. 1998.Google Scholar
Cattoretti C., Becker M.H., Key C., et al. Monoclonal antibodies against recombinant parts of the ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed sections. J. Pathol.
168:357, 1992.PubMedCrossRefGoogle Scholar
Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of prolonged cell death in situ
via specific labeling of nuclear DNA fragmentation. J. Cell. Biol.
119:493, 1992.PubMedCrossRefGoogle Scholar
Piazza G.A., Rahm A.K., Finn T.S., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res.
57:2452, 1997.PubMedGoogle Scholar
© Springer Science+Business Media New York 1999